Mon, Jan 26, 2015, 11:56 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • slumdawg2011 slumdawg2011 Oct 26, 2012 2:21 PM Flag


    IMGN tanking after mgmt finally decided to announce details of previously "undeclared" royalty terms. Glasnost!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • blackmenrock Oct 27, 2012 10:14 PM Flag

      Hey Dawg. Hi
      I'm not currently invested over there but follow it closely. SGEN's newer royalty deals are more favorable than the IMGN/Roche deal. Older ones I think are about the same as IMGN's. Plus there are some outright 50/50 collaborations here. I think IMGN is toast for awhile. If it hit's $8 I think I'll get back in. They have more buyout potential.
      I'm slowly accumulating here. About 20% of where I'd like to be.
      What's your guess on what this will do on earnings?

      • 1 Reply to blackmenrock
      • Not sure about Adcetris sales forecast. Off-label use could always provide a surprise upside. I think the Abbott (25M), two ph2 drugs for Roche (maybe 10-15M), and Eu approval if it comes in November (25M from Takeda), will all go in for next qtr, but I am not really sure. Only thing I know is more money seems to be coming into SGEN than IMGN at this time. CLDX drug may also get accelerated approval. I don't know if IMGN is a more attractive buyout candidate than SGEN.

        IMGN sell-off was probably overdone because in the end, T-DM1 sales will be exceeding 700M anyway for US so IMGN still gets the 5%. Perhaps analysts were hoping for starting at 5% and somewhere at 7% for higher sales. With priority review decision pending for T-DM1 and eventual approval (hopefully before Christmas), right about now maybe a good time to get back in, but my guess is always as "bad" as yours. $8 maybe too low of an entry target. 70% of HER2+ patients don't respond to Herceptin. Thing is, I think Roche should just drop Herceptin and Perjeta and focus on T-DM1. They're just trying to squeeze as much of patients and insurers monies from less potent drugs. FDA is not helping either.

33.02+0.72(+2.23%)Jan 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.